Etidocaine
Duranest (etidocaine) is a small molecule pharmaceutical. Etidocaine was first approved as Duranest on 1982-01-01. It is used to treat postoperative pain in the USA. It is known to target sodium channel protein type 2 subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Etidocaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DURANEST | AstraZeneca | N-017751 DISCN | 1982-01-01 | 2 products, RLD |
Hide discontinued
Epinephrine
+
Etidocaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DURANEST | AstraZeneca | N-017751 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Epinephrine bitartrate
+
Etidocaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DURANEST | AstraZeneca | N-017751 DISCN | 1982-01-01 | 2 products, RLD |
| DURANEST | Dentsply Pharmaceutical | N-021384 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Show 2 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Etidocaine |
| INN | etidocaine |
| Description | Etidocaine is an amino acid amide in which 2-[ethyl(propyl)amino]butanoic acid and 2,6-dimethylaniline have combined to form the amide bond. Used as a local anaesthetic (amide caine), it has rapid onset and long action properties, similar to bupivacaine, and is given by injection during surgical procedures and during labour and delivery. It has a role as a local anaesthetic. |
| Classification | Small molecule |
| Drug class | local anesthetics |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C |
Identifiers
| PDB | — |
| CAS-ID | 36637-18-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL492 |
| ChEBI ID | 4904 |
| PubChem CID | 37497 |
| DrugBank | DB08987 |
| UNII ID | I6CQM0F31V (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SCN2A
SCN2A
Organism
Homo sapiens
Gene name
SCN2A
Gene synonyms
HBA, NAC2, SCN2A1, SCN2A2
NCBI Gene ID
Protein name
sodium channel protein type 2 subunit alpha
Protein synonyms
HBSC II, Sodium channel protein brain II subunit alpha, Sodium channel protein type II subunit alpha, sodium channel protein, brain type 2 alpha subunit, sodium channel, voltage-gated, type II, alpha 1 polypeptide, sodium channel, voltage-gated, type II, alpha 2 polypeptide, sodium channel, voltage-gated, type II, alpha subunit, voltage-gated sodium channel subtype II, Voltage-gated sodium channel subunit alpha Nav1.2, voltage-gated sodium channel type II alpha subunit
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 428 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use